Eli Lilly and Co (LLY):企業の財務・戦略的SWOT分析

◆英語タイトル:Eli Lilly and Co (LLY) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH4003FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:79
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥51,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Eli Lilly and Co (LLY) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Eli Lilly and Co (Lilly) is a healthcare company that discovers, develops and markets human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men’s health and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.

Eli Lilly and Co Key Recent Developments

Apr 06,2021: Lilly Confirms Date and Conference Call for First-Quarter 2021 Financial Results Announcement
Mar 23,2021: Cleveland Clinic collaborates with Lilly, anthem to add new heart surgery option for Lilly health plan members
Mar 10,2021: Lilly announces details of presentations at 2021 American Association for Cancer Research
Mar 09,2021: Lilly announces leadership transitions in manufacturing and ethics and compliance organizations
Mar 01,2021: US to buy more doses of Lilly’s Covid-19 antibody therapy

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Eli Lilly and Co – Key Facts
Eli Lilly and Co – Key Employees
Eli Lilly and Co – Key Employee Biographies
Eli Lilly and Co – Major Products and Services
Eli Lilly and Co – History
Eli Lilly and Co – Company Statement
Eli Lilly and Co – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Eli Lilly and Co – Business Description
Product Category: Diabetes
Performance
Product Category: Immunology
Performance
Product Category: Neuroscience
Performance
Product Category: Oncology
Performance
Product Category: Other
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Other Foreign Countries
Performance
Geographical Segment: United States
Performance
R&D Overview
Eli Lilly and Co – Corporate Strategy
Eli Lilly and Co – SWOT Analysis
SWOT Analysis – Overview
Eli Lilly and Co – Strengths
Eli Lilly and Co – Weaknesses
Eli Lilly and Co – Opportunities
Eli Lilly and Co – Threats
Eli Lilly and Co – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Eli Lilly and Co, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 06, 2021: Lilly Confirms Date and Conference Call for First-Quarter 2021 Financial Results Announcement
Mar 23, 2021: Cleveland Clinic collaborates with Lilly, anthem to add new heart surgery option for Lilly health plan members
Mar 10, 2021: Lilly announces details of presentations at 2021 American Association for Cancer Research
Mar 09, 2021: Lilly announces leadership transitions in manufacturing and ethics and compliance organizations
Mar 01, 2021: US to buy more doses of Lilly’s Covid-19 antibody therapy
Feb 19, 2021: Lilly, Rigel enter $960m deal to develop RIPK1 inhibitors
Feb 17, 2021: Kimberly H. Johnson elected to Lilly Board of Directors
Feb 10, 2021: FDA grants EUA to Eli Lilly’s antibody therapies for Covid-19
Feb 09, 2021: Lilly appoints Anat Ashkenazi Chief Financial Officer
Feb 02, 2021: Lilly, US health systems partner to set up Covid-19 antibody infusion centres
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Eli Lilly and Co, Key Facts
Eli Lilly and Co, Key Employees
Eli Lilly and Co, Key Employee Biographies
Eli Lilly and Co, Major Products and Services
Eli Lilly and Co, History
Eli Lilly and Co, Subsidiaries
Eli Lilly and Co, Joint Venture
Eli Lilly and Co, Key Competitors
Eli Lilly and Co, Ratios based on current share price
Eli Lilly and Co, Annual Ratios
Eli Lilly and Co, Annual Ratios (Cont...1)
Eli Lilly and Co, Annual Ratios (Cont...2)
Eli Lilly and Co, Interim Ratios
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Eli Lilly and Co, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Eli Lilly and Co (LLY):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bangkok Insurance Pcl
    Bangkok Insurance Pcl - Strategy, SWOT and Corporate Finance Report Summary Bangkok Insurance Pcl - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Mediware Information Systems Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Mediware Information Systems Inc (Mediware), a subsidiary of TPG Capital is a healthcare solutions company that designs, develops and commercializes specialized healthcare software. It provides software to healthcare and human service providers and payers. The company’s portfolio of solution …
  • Great Western Oil & Gas Co LLC:石油・ガス:M&Aディール及び事業提携情報
    Summary Great Western Oil & Gas Co LLC (GWOG), a subsidiary of The Broe Group, is an oil and gas company that offers exploration and production of oil and gas properties. The company operates through developmental drilling, and corporate and property acquisition operations. Its core area of operatio …
  • Taishin International Bank Co Ltd:企業の戦略・SWOT・財務分析
    Taishin International Bank Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Taishin International Bank Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • The Vanguard Group, Inc.:企業の戦略的SWOT分析
    The Vanguard Group, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Antibe Therapeutics Inc (ATE)-製薬・医療分野:企業M&A・提携分析
    Summary Antibe Therapeutics Inc (Antibe) is a biotechnology company that designs and develops drug candidates for chronic pain and inflammation; and regenerative medicine. The company discovers and commercialize novel drugs, biologics and medical devices. It offers lead compound ATB-346, a naproxen …
  • American Cancer Society Inc:企業の戦略的SWOT分析
    American Cancer Society Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Bacardi Limited:企業の戦略・SWOT・財務情報
    Bacardi Limited - Strategy, SWOT and Corporate Finance Report Summary Bacardi Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • IDT Biologika GmbH-製薬・医療分野:企業M&A・提携分析
    Summary IDT Biologika GmbH (IDT Biologika), a subsidiary of Klocke Pharma-Service GmbH, is a manufacturer of vaccines and bio-pharmaceuticals products. It offers services which include integrated development and manufacturing services in four major areas of animal health, vaccines, pharmaceuticals a …
  • Henry Schein, Inc.:企業の戦略・SWOT・財務情報
    Henry Schein, Inc. - Strategy, SWOT and Corporate Finance Report Summary Henry Schein, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Nacco Industries Inc:企業の戦略・SWOT・財務情報
    Nacco Industries Inc - Strategy, SWOT and Corporate Finance Report Summary Nacco Industries Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Parker Institute for Cancer Immunotherapy:製薬・医療:M&Aディール及び事業提携情報
    Summary Parker Institute for Cancer Immunotherapy (Parker Institute), a subsidiary of The Parker Foundation is a nonprofit public benefit corporation which focuses on the development of immune therapies for the treatment of cancer. The institute coordinates together the scientists, nonprofits, acade …
  • PhaseRx Inc (PZRX)-医療機器分野:企業M&A・提携分析
    Summary PhaseRx Inc (PhaseRx), formerly PhaseRx Pharmaceuticals Inc is a healthcare products provider that conducts research and develops RNA nanomedicines for the treatment of orphan diseases. The company discovers and develops drugs based on SMARTT polymer technology, which offers mRNA delivery te …
  • Vale SA:企業のM&A・事業提携・投資動向
    Vale SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Vale SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital ra …
  • Ampio Pharmaceuticals Inc (AMPE):製薬・医療:M&Aディール及び事業提携情報
    Summary Ampio Pharmaceuticals Inc (Ampio), formerly Chay Enterprises Inc is a biopharmaceutical company that discovers and develops novel therapeutic candidates for inflammatory conditions. The company develops compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by …
  • Puma Energy Holdings Pte Ltd:企業のM&A・事業提携・投資動向
    Puma Energy Holdings Pte Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Puma Energy Holdings Pte Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Tenaga Nasional Bhd (TENAGA):電力:M&Aディール及び事業提携情報
    Summary Tenaga Nasional Bhd (TNB) is an electricity utility that generates, transmits, distributes and supplies power. It develops, operates and maintains a portfolio of power generating units. The company produces electricity from crude oil, natural gas, hydro, coal and gas sources. TNB also suppli …
  • Manitoba Hydro-Electric Board:発電所・企業SWOT分析
    Manitoba Hydro-Electric Board - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • EuroSibEnergo Plc:企業の戦略的SWOT分析
    EuroSibEnergo Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Pharm-Olam International Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Pharm-Olam International Ltd (Pharm-Olam) is a contract research organization that offers clinical research services. The organization’s services include clinical trials, medical writing, medical monitoring, regulatory submissions, data management, biostatistics analysis, pharmacovigilance, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆